Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy
This article was originally published in RPM Report
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
You may also be interested in...
Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.